Works

Thesis

  • Mobilization of Procollagen and Lysosomes during Osteoblast Stimulation with Ascorbic Acid, 2012, UofT library.

Peer-reviewed research contributions

  • Samaei SS, Daryab M, Gholami S, Rezaee A, Fatehi N, Roshannia R, Hashemi S, Javani N, Rahmanian P, Amani-Beni R, Zandieh MA, Nabavi N, Rashidi M, Malgard N, Hashemi M, Taheriazam A. Multifunctional and stimuli-responsive liposomes in hepatocellular carcinoma diagnosis and therapy. Transl Oncol. 2024 Apr 30;45:101975. doi: 10.1016/j.tranon.2024.101975. PMID: 38692195

  • Hashem M, Mohandesi Khosroshahi E, Aliahmady M, Ghanei M, Soofi Rezaie Y, Alsadat Jafari Y, Rezaei F, Khodaparast Eskadehi R, Kia Kojoori K, Jamshidian F, Nabavi N, Rashidi M, Hasani Sadi F, Taheriazam A, Entezari M. Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism. Noncoding RNA Res. 2024 Jan 22;9(2):560-582. doi: 10.1016/j.ncrna.2024.01.009. PMID: 38515791

  • Hashemi M, Daneii P, Asadalizadeh M, Tabari K, Matinahmadi A, Bidoki SS, Motlagh YSM, Jafari AM, Ghorbani A, Dehghanpour A, Nabavi N, Tan SC, Rashidi M, Taheriazam A, Entezari M, Goharrizi MASB. Epigenetic regulation of hepatocellular carcinoma progression: MicroRNAs as therapeutic, diagnostic and prognostic factors. Int J Biochem Cell Biol. 2024 May;170:106566. doi: 10.1016/j.biocel.2024.106566. Epub 2024 Mar 20. PMID: 38513802

  • Ebrahimi N, Manavi MS, Faghihkhorasani F, Fakhr SS, Baei FJ, Khorasani FF, Zare MM, Far NP, Rezaei-Tazangi F, Ren J, Reiter RJ, Nabavi N, Aref AR, Chen C, Ertas YN, Lu Q. Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response. Cancer Metastasis Rev. 2024 Mar;43(1):457-479. doi: 10.1007/s10555-023-10162-7. Epub 2024 Jan 16. PMID: 38227149

  • Baniasadi M, Talebi S, Mokhtari K, Zabolian AH, Khosroshahi EM, Entezari M, Dehkhoda F, Nabavi N, Hashemi M. Role of non-coding RNAs in osteoporosis. Pathol Res Pract. 2024 Jan;253:155036. doi: 10.1016/j.prp.2023.155036. Epub 2023 Dec. PMID: 38134836

  • Karimi B, Mokhtari K, Rozbahani H, Peymani M, Nabavi N, Entezari M, Rashidi M, Taheriazam A, Ghaedi K, Hashemi M. Pathological roles of miRNAs and pseudogene-derived lncRNAs in human cancers, and their comparison as prognosis/diagnosis biomarkers. Pathol Res Pract. 2024 Jan;253:155014. doi: 10.1016/j.prp.2023.155014. Epub 2023 Dec 12. PMID: 38128189

  • Hashemi M, Nazdari N, Gholamiyan G, Paskeh MDA, Jafari AM, Nemati F, Khodaei E, Abyari G, Behdadfar N, Raei B, Raesi R, Nabavi N, Hu P, Rashidi M, Taheriazam A, Entezari M. EZH2 as a potential therapeutic target for gastrointestinal cancers. Pathol Res Pract. 2024 Jan;253:154988. doi: 10.1016/j.prp.2023.154988. Epub 2023 Nov 29. PMID: 38118215

  • Hashemi M, Esbati N, Rashidi M, Gholami S, Raesi R, Bidoki SS, Goharrizi MASB, Motlagh YSM, Khorrami R, Tavakolpournegari A, Nabavi N, Zou R, Mohammadnahal L, Entezari M, Taheriazam A, Hushmandi K. Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer. Transl Oncol. 2024 Feb;40:101846. doi: 10.1016/j.tranon.2023.101846. Epub 2023 Dec 1. PMID: 38042134

  • Hashemi M, Khosroshahi EM, Chegini MK, Abedi M, Matinahmadi A, Hosnarody YSD, Rezaei M, Saghari Y, Fattah E, Abdi S, Entezari M, Nabavi N, Rashidi M, Raesi R, Taheriazam A. miRNAs and exosomal miRNAs in lung cancer: New emerging players in tumor progression and therapy response. Pathol Res Pract. 2023 Nov;251:154906. doi: 10.1016/j.prp.2023.154906. Epub 2023 Oct 26. PMID: 37939448

  • Sadrkhanloo M, Paskeh MDA, Hashemi M, Raesi R, Bahonar A, Nakhaee Z, Entezari M, Beig Goharrizi MAS, Salimimoghadam S, Ren J, Nabavi N, Rashidi M, Dehkhoda F, Taheriazam A, Tan SC, Hushmandi K. New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis. Pathol Res Pract. 2023 Nov;251:154902. doi: 10.1016/j.prp.2023.154902. Epub 2023 Oct 21. PMID: 37922723

  • Hashemi M, Razzazan M, Bagheri M, Asadi S, Jamali B, Khalafi M, Azimi A, Rad S, Behroozaghdam M, Nabavi N, Rashidi M, Dehkhoda F, Taheriazam A, Entezari M. Versatile function of AMPK signaling in osteosarcoma: An old player with new emerging carcinogenic functions. Pathol Res Pract. 2023 Nov;251:154849. doi: 10.1016/j.prp.2023.154849. Epub 2023 Oct 4. PMID: 37837858

  • Yenki P, Bhasin S, Liu L, Nabavi N, Cheng CW, Tam KJ, Peacock JW, Adomat HH, Tombe T, Fazli L, Ivanova L, Dusek C, Khosravi S, Guns EST, Wang Y, Buttyan R, Gleave ME, Ong CJ. Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells. Endocr Relat Cancer. 2023 Nov 6;30(12):e230010. doi: 10.1530/ERC-23-0010. PMID: 37800655

  • Tehrany PM, Rahmanian P, Rezaee A, Ranjbarpazuki G, Sohrabi Fard F, Asadollah Salmanpour Y, Zandieh MA, Ranjbarpazuki A, Asghari S, Javani N, Nabavi N, Aref AR, Hashemi M, Rashidi M, Taheriazam A, Motahari A, Hushmandi K. Multifunctional and theranostic hydrogels for wound healing acceleration: An emphasis on diabetic-related chronic wounds. Environ Res. 2023 Dec 1;238(Pt 1):117087. doi: 10.1016/j.envres.2023.117087. Epub 2023 Sep 15. PMID: 37716390

  • Sadeghi MS, Sangrizeh FH, Jahani N, Abedin MS, Chaleshgari S, Ardakan AK, Baeelashaki R, Ranjbarpazuki G, Rahmanian P, Zandieh MA, Nabavi N, Aref AR, Salimimoghadam S, Rashidi M, Rezaee A, Hushmandi K. Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development. Environ Res. 2023 Nov 15;237(Pt 2):117027. doi: 10.1016/j.envres.2023.117027. Epub 2023 Sep 1. PMID: 37659647

  • Zandieh MA, Farahani MH, Daryab M, Motahari A, Gholami S, Salmani F, Karimi F, Samaei SS, Rezaee A, Rahmanian P, Khorrami R, Salimimoghadam S, Nabavi N, Zou R, Sethi G, Rashidi M, Hushmandi K. Stimuli-responsive (nano)architectures for phytochemical delivery in cancer therapy. Biomed Pharmacother. 2023 Oct;166:115283. doi: 10.1016/j.biopha.2023.115283. Epub 2023 Aug 9. PMID: 37567073

  • Rezaee A, Tehrany PM, Tirabadi FJ, Sanadgol N, Karimi AS, Ajdari A, Eydivandi S, Etemad S, Rajabi R, Rahmanian P, Khorrami R, Nabavi N, Aref AR, Fan X, Zou R, Rashidi M, Zandieh MA, Hushmandi K. Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non- coding RNAs. Biomed Pharmacother. 2023 Jul 25;165:115187. doi: 10.1016/j.biopha.2023.115187. PMID: 37499452

  • Rezaei S, Nikpanjeh N, Rezaee A, Gholami S, Hashemipour R, Biavarz N, Yousefi F, Tashakori A, Salmani F, Rajabi R, Khorrami R, Nabavi N, Ren J, Salimimoghadam S, Rashidi M, Zandieh MA, Hushmandi K, Wang Y. PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation. Eur J Pharmacol. 2023 Jul 23;955:175909. doi: 10.1016/j.ejphar.2023.175909. PMID: 37490949

  • Hashemi M, Gholami S, Raesi R, Sarhangi S, Mahmoodieh B, Koohpar ZK, Goharrizi MASB, Behroozaghdam M, Entezari M, Salimimoghadam S, Zha W, Rashidi M, Abdi S, Taheriazam A, Nabavi N. Biological and therapeutic viewpoints towards role of miR-218 in human cancers: Revisiting molecular interactions and future clinical translations. Cell Signal. 2023 Sep;109:110786. doi: 10.1016/j.cellsig.2023.110786. PMID: 37380085

  • Hashemi M, Abbaszadeh S, Rashidi M, Amini N, Talebi Anaraki K, Motahhary M, Khalilipouya E, Harif Nashtifani A, Shafiei S, Ramezani Farani M, Nabavi N, Salimimoghadam S, Aref AR, Raesi R, Taheriazam A, Entezari M, Zha W. STAT3 as a newly emerging target in colorectal cancer therapy: Tumorigenesis, therapy response, and pharmacological/nanoplatform strategies. Environ Res. 2023 Jun 20;233:116458. doi: 10.1016/j.envres.2023.116458. PMID: 37348629

  • Karimi K, Mojtabavi S, Tehrany PM, Nejad MM, Rezaee A, Mohtashamian S, Hamedi E, Yousefi F, Salmani F, Zandieh MA, Nabavi N, Rabiee N, Ertas YN, Salimimoghadam S, Rashidi M, Rahmanian P, Hushmandi K, Yu W. Chitosan-based nanoscale delivery systems in hepatocellular carcinoma: Versatile bio-platform with theranostic application. Int J Biol Macromol. 2023 Jul 1;242(Pt 3):124935. doi: 10.1016/j.ijbiomac.2023.124935. PMID: 37230442

  • Hashemi M, Sabouni E, Rahmanian P, Entezari M, Mojtabavi M, Raei B, Zandieh MA, Behroozaghdam M, Mirzaei S, Hushmandi K, Nabavi N, Salimimoghadam S, Ren J, Rashidi M, Raesi R, Taheriazam A, Alexiou A, Papadakis M, Tan SC. Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance. Cell Mol Biol Lett. 2023 Apr 21;28(1):33. doi: 10.1186/s11658-023-00438-9. PMID: 37085753

  • Al-Rashidi RR, Noraldeen SAM, Kareem AK, Mahmoud AK, Kadhum WR, Ramírez- Coronel AA, Iswanto AH, Obaid RF, Jalil AT, Mustafa YF, Nabavi N, Wang Y, Wang L. Malignant function of nuclear factor-kappaB axis in prostate cancer: Molecular interactions and regulation by non-coding RNAs. Pharmacol Res. 2023 Apr 17;194:106775. doi: 10.1016/j.phrs.2023.106775. PMID: 37075872

  • Ebrahimi N, Far NP, Fakhr SS, Faghihkhorasani F, Miraghel SA, Chaleshtori SR, Rezaei-Tazangi F, Beiranvand S, Baziyar P, Manavi MS, Zarrabi A, Nabavi N, Ren J, Aref AR. The endocannabinoid system, a new gatekeeper in the pharmacology of human hepatocellular carcinoma. Environ Res. 2023 Jul 1;228:115914. doi: 10.1016/j.envres.2023.115914. PMID: 37062475

  • Hashemi M, Zandieh MA, Ziaolhagh S, Mojtabavi S, Sadi FH, Koohpar ZK, Ghanbarirad M, Haghighatfard A, Behroozaghdam M, Khorrami R, Nabavi N, Ren J, Reiter RJ, Salimimoghadam S, Rashidi M, Hushmandi K, Taheriazam A, Entezari M. Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective. Biochim Biophys Acta Mol Basis Dis. 2023 Apr 5;1869(5):166714. doi: 10.1016/j.bbadis.2023.166714. Epub ahead of print. PMID: 37028606

  • Almajidi YQ, Kadhim MM, Alsaikhan F, Turki Jalil A, Hassan Sayyid N, Alexis Ramírez-Coronel A, Hassan Jawhar Z, Gupta J, Nabavi N, Yu W, Ertas YN. Doxorubicin-loaded micelles in tumor cell-specific chemotherapy. Environ Res. 2023 Mar 21;227:115722. doi: 10.1016/j.envres.2023.115722. Epub ahead of print. PMID: 36948284

  • Sabouni E, Nejad MM, Mojtabavi S, Khoshduz S, Mojtabavi M, Nadafzadeh N, Nikpanjeh N, Mirzaei S, Hashemi M, Aref AR, Khorrami R, Nabavi N, Ertas YN, Salimimoghadam S, Zandieh MA, Rahmanian P, Taheriazam A, Hushmandi K. Unraveling the function of epithelial-mesenchymal transition (EMT) in colorectal cancer: Metastasis, therapy response, and revisiting molecular pathways. Biomed Pharmacother. 2023 Apr;160:114395. doi: 10.1016/j.biopha.2023.114395. Epub 2023 Feb 15. PMID: 36804124

  • Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, Babaei R, Sadi FH, Rajabi R, Abkenar ZO, Rezaei S, Ren J, Nabavi N, Khorrami R, Rashidi M, Hushmandi K, Entezari M, Taheriazam A. Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies. Biomed Pharmacother. 2023 Apr;160:114392. doi: 10.1016/j.biopha.2023.114392. Epub 2023 Feb 15. PMID: 36804123

  • Hashemi M, Mirdamadi MSA, Talebi Y, Khaniabad N, Banaei G, Daneii P, Gholami S, Ghorbani A, Tavakolpournegari A, Farsani ZM, Zarrabi A, Nabavi N, Zandieh MA, Rashidi M, Taheriazam A, Entezari M, Khan H. Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents. Pharmacol Res. 2022 Nov 21:106568. doi: 10.1016/j.phrs.2022.106568. PMID: 36423787

  • Hashemi M, Hasani S, Hajimazdarany S, Mirmazloomi SR, Makvandy S, Zabihi A, Goldoost Y, Gholinia N, Kakavand A, Tavakolpournegari A, Salimimoghadam S, Nabavi N, Zarrabi A, Taheriazam A, Entezari M, Hushmandi K. Non-coding RNAs targeting notch signaling pathway in cancer: From proliferation to cancer therapy resistance. Int J Biol Macromol. 2022 Sep. 30:S0141-8130(22)02142-0. doi: 10.1016/j.ijbiomac.2022.09.203. PMID: 36191781

  • Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res. 2022 Jul 1;41(1):214. doi: 10.1186/s13046-022-02406-1. PMID: 35773731.

  • Nann P, Nabavi N, Ziafat K, Preston R, Chau A, Krausz MR, Schwarz SKW, Maclure M. Trends in opioid dispensing after common abdominal and orthopedic surgery procedures in British Columbia: a retrospective cohort analysis. Can J Anesth/J Can Anesth (2022). doi: 10.1007/s12630-022-02272-7. PMID: 35764863.

  • Ziafat K, Polderman S, Nabavi N, Preston R, Chau A, Krausz MR, Schwarz SKW, Maclure M. Opioid dispensing after Cesarean delivery in British Columbia: a historical cohort analysis from 2004 to 2019. Can J Anesth/J Can Anesth (2022). doi: 10.1007/s12630-022-02271-8. PMID: 35764863

  • Entezari M, Ghanbarirad M, Taheriazam A, Sadrkhanloo M, Zabolian A, Goharrizi MASB, Hushmandi K, Aref AR, Ashrafizadeh M, Zarrabi A, Nabavi N, Rabiee N, Hashemi M, Samarghandian S. Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling. Biomed Pharmacother. 2022 Apr 22. doi: 10.1016/j.biopha.2022.112963. PMID: 35468579

  • Madamsetty VS, Mohammadinejad R, Uzieliene I, Nabavi N, Dehshahri A, García-Couce J, Tavakol S, Moghassemi S, Dadashzadeh A, Makvandi P, Pardakhty A, Aghaei Afshar A, Seyfoddin A. Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems.ACS Biomater Sci Eng. 2022 Apr 19. doi: 10.1021/acsbiomaterials.2c00026. PMID 35439408

  • Ashrafizadeh M, Paskeh MDA, Mirzaei S, Gholami MH, Zarrabi A, Hashemi F, Hushmandi K, Hashemi M, Nabavi N, Crea F, Ren J, Klionsky DJ, Kumar AP, Wang Y. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. J Exp Clin Cancer Res 41, 105 (2022). doi: 10.1186/s13046-022-02293-6. PMID: 35317831

  • Mirzaei S, Gholami MH, Hushmandi K, Hshemi F, Zabolian A, Canadas I, Zarrabi A, Nabavi N, Aref AR, Crea F, Wang Y, Ashrafizadeh M, Kumar AP. The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol. 2022 Mar 2;15(1):18. doi: 10.1186/s13045-022-01235-1. PMID: 35236381

  • Ashrafizadeh M, Zarrabi A, Mirzaei S, Hashemi F, Samarghandian S, Zabolian A, Hushmandi K, Ang HL, Sethi G, Kumar AP, Ahn KS, Nabavi N, Khan H, Makvandi P, Varma RS. Use of Gallic acid for cancer treatment: Molecular mechanisms and improvement of efficacy by nanoformulations. Food Chem Toxicol. 2021 Sep 24:112576. doi: 10.1016/j.fct.2021.112576. PMID: 34571052.

  • Oo HZ, Lohinai Z, Khazamipour N, Lo J, Kumar G, Pihl J, Adomat H, Nabavi N, Behmanesh H, Zhai B, Dagil R, Choudhary S, Gustavsson T, Clausen TM, Esko JD, Allen JW, Thompson MA, Tran NL, Moldvay J, Dome B, Salanti A, Al-Nakouzi N, Weiss GJ, Daugaard M. Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer. Cancers (Basel). 2021 Sep 6;13(17):4489. doi: 10.3390/cancers13174489. PMID: 34503301.

  • Ashrafizadeh M, Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Raei M, Hushmandi K, Zarrabi A, Voelcker NH, Aref AR, Hamblin MR, Varma RS, Samarghandian S, Arostegi IJ, Alzola M, Kumar AP, Thakur VK, Nabavi N, Makvandi P, Tay FR, Orive G. Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression. Carbohydr Polym. 2021 Nov 15;272:118491. doi: 10.1016/j.carbpol.2021.118491. Epub 2021 Jul 27. PMID: 34420747.

  • Ashrafizadeh M, Zarrabi A, Orouei S, Zabolian A, Saleki H, Azami N, Bejandi AK, Mirzaei S, Janaghard MN, Hushmandi K, Nabavi N, Baradaran B, Kumar AP, Makvandi P, Samarghandian S, Khan H, Hamblin MR. Interplay between SOX9 transcription factor and microRNAs in cancer. Int J Biol Macromol. 2021 May 3:S0141-8130(21)00958-2. doi: 10.1016/j.ijbiomac.2021.04.185. PMID: 33957202.

  • Mather RL, Parolia A, Carson SE, Venalainen E, Roig-Carles D, Jaber M, Chu SC, Alborelli I, Wu R, Lin D, Nabavi N, Jachetti E, Colombo MP, Xue H, Pucci P, Ci X, Hawkes C, Li Y, Pandha H, Ulitsky I, Marconett C, Quagliata L, Jiang W, Romero I, Wang Y, Crea F. The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms. Mol Oncol. 2021 Apr 1. doi: 10.1002/1878-0261.12954. Epub ahead of print. PMID: 33793068.

  • Mirzaei S, Mohammadi AT, Gholami MH, Hashemi F, Zarrabi A, Zabolian A, Hushmandi K, Makvandi P, Samec M, Liskova A, Kubatka P, Nabavi N, Aref AR, Ashrafizadeh M, Khan H, Najafi M. Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance. Pharmacol Res. 2021 Mar 24;167:105575. doi: 10.1016/j.phrs.2021.105575. Epub ahead of print. PMID: 33771701.

  • Ashrafizaveh S, Ashrafizadeh M, Zarrabi A, Husmandi K, Zabolian A, Shahinozzaman M, Aref AR, Hamblin MR, Nabavi N, Crea F, Wang Y, Ahn KS. Long non-coding RNA in the doxorubicin resistance of cancer cells. Cancer Lett. 2021 Mar 22:S0304-3835(21)00123-3. doi: 10.1016/j.canlet.2021.03.018. Epub ahead of print. PMID: 33766750.

  • Mirzaei S, Gholami MH, Mahabady MK, Nabavi N, Zabolian A, Banihashemi SM, Haddadi A, Entezari M, Hushmandi K, Makvandi P, Samarghandian S, Zarrabi A, Ashrafizadeh M, Khan H. Pre-clinical investigation of STAT3 pathway in bladder cancer: Paving the way for clinical translation. Biomed Pharmacother. 2021 Jan;133:111077. doi: 10.1016/j.biopha.2020.111077. Epub 2020 Dec 4. PMID:33378975.

  • Ashrafizadeh M, Hushmandi K, Rahmani Moghadam E, Zarrin V, Hosseinzadeh Kashani S, Bokaie S, Najafi M, Tavakol S, Mohammadinejad R, Nabavi N, Hsieh CL, Zarepour A, Zare EN, Zarrabi A, Makvandi P. Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer. Bioengineering (Basel). 2020 Aug 10;7(3):91. doi: 10.3390/bioengineering7030091. PMID: 32784981; PMCID: PMC7552721.

  • Shrestha R, Nabavi N, Volik S, Anderson S, Haegert A, McConeghy B, Sar F, Brahmbhatt S, Bell R, Le Bihan S, Wang Y, Collins C, Churg A. Well- Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma. Cancers (Basel). 2020 Jun 13;12(6):1568. doi: 10.3390/cancers12061568. PMID: 32545767; PMCID: PMC7352777.

  • Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, Shukin R, Bell RH, McConeghy B, Haegert A, Brahmbhatt S, Li E, Oo HZ, Hurtado-Coll A, Fazli L, Zhou J, McConnell Y, McCart A, Lowy A, Morin GB, Chen T, Daugaard M, Sahinalp SC, Hach F, Le Bihan S, Gleave ME, Wang Y, Churg A, Collins CC. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med. 2019 Feb 18;11(1):8. doi: 10.1186/s13073-019-0620-3. PMID: 30777124; PMCID: PMC6378747.

  • Nabavi N, Wei J, Lin D, Collins CC, Gout PW, Wang Y. Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts. Front Genet. 2018 Jul 4;9:232. doi: 10.3389/fgene.2018.00232. PMID: 30022998; PMCID: PMC6040159.

  • Choi SYC, Ettinger SL, Lin D, Xue H, Ci X, Nabavi N, Bell RH, Mo F, Gout PW, Fleshner NE, Gleave ME, Collins CC, Wang Y. Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. Cancer Med. 2018 Jun 14;7(7):3385–92. doi: 10.1002/cam4.1587. Epub ahead of print. PMID: 29905005; PMCID: PMC6051138.

  • Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience. 2018 Jun 1;7(6):giy050. doi: 10.1093/gigascience/giy050. PMID: 29757368; PMCID: PMC6007253.

  • Qu S, Xue H, Dong X, Lin D, Wu R, Nabavi N, Collins CC, Gleave ME, Gout PW, Wang Y. Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. Int J Cancer. 2018 Jul 15;143(2):419-429. doi: 10.1002/ijc.31310. Epub 2018 Mar 1. PMID: 29441566; PMCID: PMC6001442.

  • Nabavi N, Saidy NRN, Venalainen E, Haegert A, Parolia A, Xue H, Wang Y, Wu R, Dong X, Collins C, Crea F, Wang Y. miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. Sci Rep. 2017 Jun 22;7(1):4079. doi: 10.1038/s41598-017-03731-8. PMID: 28642484; PMCID: PMC5481412.

  • Lin D, Ettinger SL, Qu S, Xue H, Nabavi N, Choi SYC, Bell RH, Mo F, Haegert AM, Gout PW, Fleshner N, Gleave ME, Pollak M, Collins CC, Wang Y. Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. Oncotarget. 2017 Apr 18;8(16):25928-25941. doi: 10.18632/oncotarget.15237. PMID: 28460430; PMCID: PMC5432227.

  • Nabavi N, Bennewith KL, Churg A, Wang Y, Collins CC, Mutti L. Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. Genes Cancer. 2016 Nov;7(11-12):340-354. doi: 10.18632/genesandcancer.124. PMID: 28191281; PMCID: PMC5302036.

  • Kim SM, Wang Y, Nabavi N, Liu Y, Correia MA. Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame. Drug Metab Rev. 2016 Aug;48(3):405-33. doi: 10.1080/03602532.2016.1195403. Epub 2016 Jun 20. PMID: 27320797; PMCID: PMC5094896.

  • Shin J, He M, Liu Y, Paredes S, Villanova L, Brown K, Qiu X, Nabavi N, Mohrin M, Wojnoonski K, Li P, Cheng HL, Murphy AJ, Valenzuela DM, Luo H, Kapahi P, Krauss R, Mostoslavsky R, Yancopoulos GD, Alt FW, Chua KF, Chen D. SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep. 2013 Nov 14;5(3):654-665. doi: 10.1016/j.celrep.2013.10.007. Epub 2013 Nov 7. Erratum in: Cell Rep. 2013 Dec 12;5(5):1479. PMID: 24210820; PMCID: PMC3888240.

  • Pustylnik S, Fiorino C, Nabavi N, Zappitelli T, da Silva R, Aubin JE, Harrison RE. EB1 levels are elevated in ascorbic Acid (AA)-stimulated osteoblasts and mediate cell-cell adhesion-induced osteoblast differentiation. J Biol Chem. 2013 Jul 26;288(30):22096-110. doi: 10.1074/jbc.M113.481515. Epub 2013 Jun 5. PMID: 23740245; PMCID: PMC3724663.

  • Nabavi N, Pustylnik S, Harrison RE. Rab GTPase mediated procollagen trafficking in ascorbic acid stimulated osteoblasts. PLoS One. 2012;7(9):e46265. doi: 10.1371/journal.pone.0046265. Epub 2012 Sep 26. PMID: 23050002; PMCID: PMC3458846.

  • Durand M, Komarova SV, Bhargava A, Trebec-Reynolds DP, Li K, Fiorino C, Maria O, Nabavi N, Manolson MF, Harrison RE, Dixon SJ, Sims SM, Mizianty MJ, Kurgan L, Haroun S, Boire G, de Fatima Lucena-Fernandes M, de Brum-Fernandes AJ. Monocytes from patients with osteoarthritis display increased osteoclastogenesis and bone resorption: the In Vitro Osteoclast Differentiation in Arthritis study. Arthritis Rheum. 2013 Jan;65(1):148-58. doi: 10.1002/art.37722. PMID: 23044761.

  • Nabavi N, Khandani A, Camirand A, Harrison RE. Effects of microgravity on osteoclast bone resorption and osteoblast cytoskeletal organization and adhesion. Bone. 2011 Nov;49(5):965-74. doi: 10.1016/j.bone.2011.07.036. Epub 2011 Aug 2. PMID:21839189.

  • Hassanzadeh A, Nitsche M, Armstrong S, Nabavi N, Harrison R, Dixon SJ, Langbein U, Mittler S. Optical waveguides formed by silver ion exchange in Schott SG11 glass for waveguide evanescent field fluorescence microscopy: evanescent images of HEK293 cells. J Biomed Opt. 2010 May-Jun;15(3):036018. doi: 10.1117/1.3443796. PMID:20615020.

  • Nabavi N, Urukova Y, Cardelli M, Aubin JE, Harrison RE. Lysosome dispersion in osteoblasts accommodates enhanced collagen production during differentiation. J Biol Chem. 2008 Jul 11;283(28):19678-90. doi: 10.1074/jbc.M802517200. Epub 2008 May 7. PMID: 18463099.

Pre-prints, reviews, and abstracts

1: Mohammad Ali Taheri, Gholamreza Zarrini, Sara Torabi, Noushin Nabavi, Farid Semsarha, Influence of Fara-darmani Consciousness Field on Bacterial Population Growth, bioRxiv 2021.01.08.426007; doi:10.1101/2021.01.08.426007.

2: Ferrarini, Mariana, Vanessa Aguiar-Pulido, Eric T. Dawson, Andrea Guarracino, Andreas Gruber, Nabavi, Noushin, Lukas Heumos, Alexander Kanitz, et al. 2020. Global Analysis of Human Sars-cov-2 Infection and Host-virus Interaction. BioHackrXiv. May 14, 2020. doi:10.37044/osf.io/b4zkp.

3: Al Nakouzi, Nader; Wang, Chris Kedong; Nelepcu, Irina; Crouzit, Coralie; Nabavi, Noushin; Almami, Amal; Oo, Htoo Zarni; Clausen, Thomas Mandel; Gustavsson, Tobias; Salanti, Ali; Daugaard, Mads. Expression and regulation of chondroitin sulfate in prostate cancer, 2018, American Association for Cancer Research.

4: Shrestha, Raunak; Nabavi, Noushin; Lin, Yen-Yi; Mo, Fan; Anderson, Shawn; Volik, Stanislav; Adomat, Hans H; Lin, Dong; Xue, Hui; Dong, Xin; Integrated Multi-omics Molecular Subtyping Predicts Therapeutic Vulnerability in Malignant Peritoneal Mesothelioma, bioRxiv, 243477, 2018, Cold Spring Harbor Laboratory.

5: Nabavi, Noushin; Organelles enter the game of aging related aggregation and retention of misfolded proteins, Journal of Postdoctoral Research, PDJ, February, 2015.

6: Nabavi, Noushin; Protein turnover: to self-eat or not to self-eat, that’s the question, Journal of Postdoctoral Research, PDJ, January, 2014.

7: Nabavi, Noushin; YAP/TAZ Join the Play with β-catenin to Orchestrate Wnt Signaling, Journal of Postdoctoral Research, PDJ, November, 2014.

8: Nabavi, Noushin; Can aging be reversed? Journal of Postdoctoral Research, PDJ, 2014.

9: Nabavi, Noushin; Cancer-associated PTEN: Structural and Functional Characterization, Journal of Postdoctoral Research, PDJ, 2014.

Book chapter contributions

1: Nabavi N, Wei J, Lin D, Collins CC, Gout PW, Wang Y. Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts. Front Genet. 2018 Jul 4; 9:232.

2: Nabavi, Noushin; Roberts, Morgan E; Crea, Francesco; Collins, Colin C; Wang, Yuzhuo; Bishop, Jennifer L; Immuno-oncology of Dormant Tumours: Tumor Dormancy and Recurrence, Cancer Drug Discovery and Development, Pages 51-60, 2017.

3: Noushin Nabavi, Susan L. Ettinger, Francesco Crea, Yuzhuo Wang, Colin C. Collins: Biological and Clinical Evidence for Metabolic Dormancy in Solid Tumors Post Therapy,Tumor Dormancy and Recurrence, Cancer Drug Discovery and Development, Pages 17-29, 2017.

4: Noushin Nabavi, Red, Black, and White paintings, a collection. Amazon, 2014.

Science policy research, opinions, and perspectives

1: Noushin Nabavi, Healthwiser: Monitoring and evaluation of surgical outcomes; Human Health and Services Library at the BC Ministry of Health, BC-Gov, December 2020.

2: Canadian Association of Postdoctoral Scholars’ Year in Review at Annual General Meeting, CAPS-ACSP, December 2020.

3: McGuirk, Shawn; Sultmanis, Stefanie; Westwood, Alana R; Woolfson, Kathlyn N; Nabavi, Noushin:Boosting the volume and speed of genetic sequencing comes with challenges, iPolitics, November 2020.

4: Nabavi, Noushin. “Initiating an Experiment.” Zenodo, 2020. doi:10.5281/zenodo.4083752, OpenAIRE, October 2020.

5: Noushin Nabavi; Coronavirus shining a spotlight on homo sapiens, Canadian Science Policy Centre Editorial, June 2020.

6: Christine Gibb, Noushin Nabavi, Qutuba Karwi, Emma Griffiths; Limiting the negative impact of the COVID-19 pandemic on Canadian postdoctoral scholars, Canadian Science Policy Centre Editorial, May 2020.

7: McGuirk, Shawn; Sultmanis, Stefanie; Westwood, Alana R; Woolfson, Kathlyn N; Nabavi, Noushin: The Frontiers of DNA Regulation: Developing a National Policy Framework Encouraging Transparency, Security, and Cost-efficiency of Genetic Technology and Data; Policy Memo, JSPC, April 2020.

Blog posts

1: On the Woman, Life, Freedom movement in Iran , The Conversation, November 2022.
2: Open and reproducible workflows in the public service, booklet, February 2021.
3: Make a résumé using code, blog, Jan 2021.
4: Initiating an experiment in the public service booklet, November 2020.
5: To code or not to code, Data Driven Investor, Apr 13, 2020.
6: Hacking Disease and Death, Medium, Jun 30, 2019.
7: From messy to tidy: the case for a data science workflow Data Driven Investor, May 4, 2019.
8: Disruption by Design, Data Driven Investor, Nov 30, 2018.
9: Technical Considerations for Longitudinal Data Analyses Data Driven Investor, Oct 24, 2018.
10: Menu for preparing data & serving it cold Data Driven Investor, Oct 19, 2018.
11: Metacognition in the Data Age, Data Driven Investor, Oct 6, 2018.
12: Data Renaissance: Creating Data-driven Cultures Data Driven Investor, Sep 21, 2018.
13: Many Career Paths for PhDs, UCSF Synapse, November 19, 2014.
14: The legend of Gilgamesh, Medium, August 01, 2014.
15: The legend of Gilgamesh, Ancient Origins, August 2014.
16: Photoblog, elephile.
17: Blog, elephile, 2008-2017.

1: Best of the Wwest podcast at SFU, February 2021.
2: AI powered Healthcare Solutions Against COVID19, Women in Big Data, May 2020.
3: CO SOL video for Zurich hackathon, March 2020.
4: New research suggests immunotherapy could help nearly 50 per cent of patients with rare mesothelioma, Terry Fox News, June 2019.
5: Postdoc Careers Panel at Research Day, UBC October 2018.
6: R-Ladies at Open Source Summit North America, IBM Developer Blog, October 2018.
7: Supporting Rare Disease Research with BeHeard Technology award, 2017.
8: First-person account: Graduate student turns rocket scientist, University of Toronto, Jan 28, 2008.
9: Bone cells space out, The Star, March 6, 2008.
10: Blasting off: Professor’s research goes up in space, University of Toronto, Sep 24, 2007.

Software projects

1: CO-SOL: Connecting Solidarity is an app that matches suppliers and demanders of resources, which are essential for survival in the fight against COVID-19, Devpost hackathon

2: Tidying Statistics Canada’s tax/census data, BC Ministry of Citizens’ Services

3: Developing economic indices using national tax data, BC Ministry of Citizens’ Services

4: Analysis of open COVID data for BC as released by Johns Hopkins University Center for Systems Science and Engineering JHU CSSE

5: Anatomy of Morbidity as part of Hackseq Hackathon Project at UBC